NAT2 Gene Variations and Cancer Risk
Author Information
Author(s): Juergen Borlak, Stella Marie Reamon-Buettner
Primary Institution: Fraunhofer Institute of Toxicology and Experimental Medicine
Hypothesis
Does the NAT2 gene polymorphism influence the risk of colon and lung cancer?
Conclusion
The study found no overall association between NAT2 genotypes and the risk of colon or lung cancer.
Supporting Evidence
- The study genotyped 243 healthy controls, 92 colon cancer patients, and 67 lung cancer patients.
- No significant differences in NAT2 allele and genotype frequencies were found between cancer patients and controls.
- Certain genotypes were absent in colon cancer patients compared to controls.
Takeaway
The NAT2 gene can change how our bodies process certain drugs and chemicals, but this study didn't find a link between its variations and colon or lung cancer risk.
Methodology
Genotyping of three NAT2 gene variations in 92 colon cancer patients, 67 lung cancer patients, and 243 healthy controls using PCR-RFLP assays.
Limitations
The study had a small sample size and did not account for certain exposure variables.
Participant Demographics
Healthy unrelated Caucasian individuals and cancer patients.
Statistical Information
Confidence Interval
95% CI 0.79–2.10 for colon cancer; 95% CI 0.48–1.45 for lung cancer
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website